MedPath
Found 35 clinical trials|View Analysis
Sort by:

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1
Not yet recruiting
Conditions
Locally Advanced Cervical Carcinoma
Locally Advanced Colorectal Carcinoma
Locally Advanced Malignant Solid Neoplasm
Locally Advanced Melanoma
Locally Advanced Pancreatic Ductal Adenocarcinoma
Locally Advanced Renal Cell Carcinoma
Metastatic Cervical Carcinoma
Metastatic Colorectal Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Interventions
Biological: Aldesleukin
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Excisional Biopsy
Drug: Fludarabine
Procedure: Magnetic Resonance Imaging
Procedure: Standard Treatment
Biological: Therapeutic Tumor Infiltrating Lymphocytes
First Posted Date
2024-10-03
Last Posted Date
2024-10-03
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
12
Registration Number
NCT06626256
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Phase 1
Recruiting
Conditions
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Metastatic Gastroesophageal Junction Adenocarcinoma
Unresectable Gastric Carcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma
Unresectable Malignant Solid Neoplasm
Clinical Stage III Gastric Cancer AJCC v8
Locally Advanced Gastroesophageal Junction Adenocarcinoma
Clinical Stage IV Gastric Cancer AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Locally Advanced Gastric Carcinoma
Interventions
Drug: Azenosertib
Procedure: Biospecimen Collection
Procedure: Biopsy
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Biological: Trastuzumab Deruxtecan
First Posted Date
2024-04-15
Last Posted Date
2024-12-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
48
Registration Number
NCT06364410
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Phase 1
Recruiting
Conditions
Metastatic Colorectal Carcinoma
Metastatic Malignant Solid Neoplasm
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma
Unresectable Malignant Solid Neoplasm
Interventions
Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Capecitabine
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
First Posted Date
2023-04-07
Last Posted Date
2024-11-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT05803382
Locations
🇺🇸

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States

🇺🇸

Siteman Cancer Center-South County, Saint Louis, Missouri, United States

🇺🇸

Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States

and more 16 locations

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

Phase 1
Recruiting
Conditions
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Diagnostic Imaging
Biological: Novobiocin Sodium
First Posted Date
2023-01-18
Last Posted Date
2025-01-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
31
Registration Number
NCT05687110
Locations
🇺🇸

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

and more 13 locations

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Peposertib
Procedure: Positron Emission Tomography
Drug: Tuvusertib
First Posted Date
2023-01-18
Last Posted Date
2025-01-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
66
Registration Number
NCT05687136
Locations
🇺🇸

National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States

🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 3 locations

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2
Recruiting
Conditions
Metastatic HER2-Negative Breast Carcinoma
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Recurrent Endometrial Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Malignant Female Reproductive System Neoplasm
Recurrent Ovarian Carcinoma
Unresectable HER2-Negative Breast Carcinoma
Unresectable Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Interventions
Procedure: Biopsy
Drug: Alpelisib
Drug: Binimetinib
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Ipatasertib
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Nilotinib Hydrochloride Monohydrate
Biological: Panitumumab
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Drug: Sotorasib
Drug: Olaparib
Drug: Fluorouracil
Drug: Neratinib Maleate
Procedure: Mutation Carrier Screening
Drug: Leucovorin
Drug: Fulvestrant
Drug: Selumetinib Sulfate
Procedure: Positron Emission Tomography
Drug: Palbociclib
Procedure: Multigated Acquisition Scan
Drug: Oxaliplatin
First Posted Date
2022-10-03
Last Posted Date
2025-01-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
2900
Registration Number
NCT05564377
Locations
🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States

🇺🇸

CTCA at Western Regional Medical Center, Goodyear, Arizona, United States

and more 422 locations

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial

Phase 2
Recruiting
Conditions
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
First Posted Date
2022-09-26
Last Posted Date
2025-01-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
33
Registration Number
NCT05554380
Locations
🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States

🇺🇸

Kingman Regional Medical Center, Kingman, Arizona, United States

and more 195 locations

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Phase 2
Recruiting
Conditions
Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
Interventions
Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Diagnostic Imaging
Drug: Talazoparib
First Posted Date
2022-04-14
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
88
Registration Number
NCT05327010
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

City of Hope at Irvine Lennar, Irvine, California, United States

🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 31 locations

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Locally Advanced Gastric Adenocarcinoma
Locally Advanced Gastroesophageal Junction Adenocarcinoma
Locally Advanced Skin Squamous Cell Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Clinical Stage IVB Gastric Cancer AJCC v8
Locally Advanced Renal Cell Carcinoma
Interventions
Drug: Cyclophosphamide
Biological: Neoantigen Peptide Vaccine
Biological: Pembrolizumab
Biological: Sargramostim
First Posted Date
2022-03-08
Last Posted Date
2024-06-12
Lead Sponsor
Mayo Clinic
Target Recruit Count
36
Registration Number
NCT05269381
Locations
🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Phase 1
Suspended
Conditions
Refractory Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Triple-Negative Breast Carcinoma
Unresectable Malignant Solid Neoplasm
Interventions
Drug: BET Bromodomain Inhibitor ZEN-3694
Drug: Binimetinib
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
First Posted Date
2021-11-08
Last Posted Date
2024-12-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
42
Registration Number
NCT05111561
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

🇺🇸

University of Texas Medical Branch, Galveston, Texas, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath